J. Prevost

The combination of three CD4-induced antibodies targeting highly conserved Env regions with a small CD4-mimetic achieves potent ADCC activity

This paper combines three CD4-induced antibodies with a CD4-mimetic to achieve potent ADCC activity against HIV-1-infected cells.

CD4 downregulation precedes Env expression and protects HIV-1-infected cells from ADCC mediated by non-neutralizing antibodies

The paper shows CD4 downregulation precedes Env expression in HIV-1-infected cells, making them resistant to non-neutralizing antibody-mediated ADCC.

Molecular basis for antiviral activity of pediatric neutralizing antibodies targeting SARS-CoV-2 Spike receptor binding domain

This study identifies two potent neutralizing antibodies, EH3 and EH8, from a pediatric patient that cross-neutralize SARS-CoV-2 variants and provide in vivo protection against the Delta VOC.

HIV-1 Vpu restricts Fc-mediated effector functions in vivo

This study shows that HIV-1 Vpu reduces nnAb recognition and ADCC resistance, with nnAb Fc-effector functions dependent on Env's open conformation.

Identification of a SARS-CoV-2 host metalloproteinase-dependent entry pathway differentially used by SARS-CoV-2 and variants of concern Alpha, Delta, and Omicron

This study identifies a MMP2/9-dependent entry pathway for SARS-CoV-2 and variants, showing differential usage and reduced activity in Omicron.

SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-weeks interval between doses

This study evaluates how plasma from individuals with a 16-week interval between BNT162b2 mRNA vaccine doses recognizes and neutralizes the Omicron Spike compared to other variants.

Detection of the HIV-1 accessory proteins Nef and Vpu by flow cytometry represents a new tool to study their functional interplay within a single infected CD4+ T cell

The paper develops a flow cytometry method to detect HIV-1 Nef and Vpu in CD4+ T cells, showing Vpu cannot compensate for Nef absence in ADCC susceptibility.

HIV-1 envelope glycoproteins proteolytic cleavage protects infected cells from ADCC mediated by plasma from infected individuals

This study shows that HIV-1 envelope glycoproteins proteolytic cleavage protects infected cells from ADCC by reducing the exposure of uncleaved Env to non-neutralizing antibodies.

An anti-SARS-CoV-2 non-neutralizing antibody with Fc-effector function defines a new NTD epitope and delays neuroinvasion and death in K18-hACE2 mice

Across functional boundaries: making non-neutralizing antibodies to neutralize HIV-1 and mediate Fc-mediated effector killing of infected cells

This paper designs Ab-CD4 chimeric proteins that open HIV-1 Env trimers to expose non-neutralizing epitopes, enabling both neutralization and ADCC against HIV-1.

Contribution of single mutations to selected SARS-CoV-2 emerging variants Spike antigenicity

The paper evaluates how single mutations in SARS-CoV-2 Spike protein affect antigenicity and ACE2 binding in emerging variants.

Structural Basis and Mode of Action for Two Broadly Neutralizing Antibodies Against SARS-CoV-2 Emerging Variants of Concern

This study characterizes two SARS-CoV-2 antibodies effective against variants, showing their structural basis and mechanisms of neutralization.

Impact of temperature on the affinity of SARS-CoV-2 Spike for ACE2

This study investigates how temperature affects SARS-CoV-2 Spike protein affinity for ACE2, finding increased binding at low temperatures, which is mitigated by the N501Y mutation.

Non-neutralizing antibodies targeting the immunogenic regions of HIV-1 envelope reduce mucosal infection and virus burden in humanized mice

This study shows that non-neutralizing antibodies targeting HIV-1 envelope regions reduce mucosal infection and virus burden in humanized mice through Fc-mediated effector functions.

Live imaging of SARS-CoV-2 infection in mice reveals neutralizing antibodies require Fc function for optimal efficacy

This study uses live imaging to show that neutralizing antibodies against SARS-CoV-2 need both Fab and Fc functions to effectively prevent and resolve infection in mice.

A single BNT162b2 mRNA dose elicits antibodies with Fc-mediated effector functions and boost pre-existing humoral and T cell responses

This study shows a single dose of the BNT162b2 mRNA vaccine elicits strong antibody and T cell responses, including Fc-mediated effector functions, and boosts pre-existing immunity in previously infected individuals.

Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset

This study tracks humoral immune responses in convalescent individuals up to 8 months post-SARS-CoV-2 infection, showing that IgG+ memory B cells persist while plasma antibody levels decline.

High-throughput detection of antibodies targeting the SARS-CoV-2 Spike in longitudinal convalescent plasma samples

This study tracks the decline of antibodies against the full-length SARS-CoV-2 Spike in convalescent plasma over time, showing a gradual decrease correlated with RBD-specific antibodies and days post-infection.

Major role of IgM in the neutralizing activity of convalescent plasma against SARS-CoV-2

This study shows that IgM plays a major role in neutralizing SARS-CoV-2 in convalescent plasma, with its depletion causing the greatest loss of neutralizing activity.

Real-time conformational dynamics of SARS-CoV-2 spikes on virus particles

This study uses smFRET to observe real-time conformational dynamics of SARS-CoV-2 spikes on virus particles, revealing multiple states and mechanisms of neutralization by antibodies and convalescent plasma.

Interaction of human ACE2 to membrane-bound SARS-CoV-1 and SARS-CoV-2 S glycoproteins

This study compares the cooperativity of ACE2 binding to SARS-CoV-1 and SARS-CoV-2 Spike proteins, finding that SARS-CoV-2 exhibits positive cooperativity.

Longitudinal analysis of the humoral response to SARS-CoV-2 spike RBD in convalescent plasma donors

The paper tracks antibody levels against SARS-CoV-2 RBD in convalescent plasma donors over time, finding a decline in antibodies after ~76 days post-symptoms onset.

Cross-sectional evaluation of humoral responses against SARS-CoV-2 Spike

This study evaluates humoral responses against SARS-CoV-2 Spike in 106 infected individuals, finding persistent RBD-specific IgG and declining neutralizing activity over time.

Vaccine-induced protection from homologous Tier 2 simian-human immunodeficiency virus challenge in nonhuman primates

This study shows that high serum neutralizing antibody titers from Env protein vaccination protect rhesus macaques from Tier 2 SHIV challenge, with ~1:500 ID50 titers providing over 90% protection.